Duvelisib is a dual phosphoinositide-3-kinase (PI3K) delta and PI3K gamma inhibitor. The delta and gamma isozymes are selectively expressed in leukocytes. This article (at Dr. Melvin Crasto’s blog newdrugapprovals.org) discusses the synthesis of Duvelisib and mentions additional clinical trials underway including a phase II trial for the treatment of patients with mild asthma undergoing allergen challenge, for the treatment of rheumatoid arthritis and for the treatment of refractory indolent non-Hodgkin’s lymphoma. Phase I clinical trials for the treatment of advanced hematological malignancies (including T-cell lymphoma and mantle cell lymphoma). The drug was originally developed at Takeda subsidiary Intellikine.
Infinity and AbbVie partner to develop and commercialise Duvelisib for cancer… for the treatment of chronic lymphocytic leukemia
November 8, 2014 by sjwilliamspa
Posted in Cancer and Current Therapeutics, CANCER BIOLOGY & Innovations in Cancer Therapy, Disease Biology, Small Molecules in Development of Therapeutic Drugs, Drug Delivery Platform Technology, Enzymes and isoenzymes, Kinase, Translational Science | Tagged B-cell chronic lymphocytic leukemia, Cancer - General, Chemotherapy, Clinical trial, CLL, duvelisib, gene expression, isoforms, medicinal chemistry, Non-Hodgkin lymphoma, PI3 kinase, PI3K/AKT pathway, T cell lymphomas | Leave a Comment
Follow Blog via Email
-
Recent Posts
- Omecamtiv mecarbil – A study examined efficacy and tolerability in Heart Failure patients with SBP ≤100 mmHg enrolled in GALACTIC-HF May 23, 2022
- Sperm epigenetic clock and pregnancy outcomes May 14, 2022
- Lessons on the Frontier of Gene & Cell Therapy – The Disruptive Dozen 12 #GCT Breakthroughs that are revolutionizing Healthcare May 9, 2022
- Relevance of Twitter.com forthcoming Payment System for Scientific Content Promotion and Monetization May 9, 2022
- Tweets at #WMIF2022 by @pharma_BI & @AVIVA1950 and all Retweets of these Tweets – 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON May 7, 2022
- Data Science: Step by Step – A Resource for LPBI Group’s One-Year Internship in IT, IS, DS May 7, 2022
- 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON • IN-PERSON May 1, 2022
- We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022 April 25, 2022
- The durability of T cells versus the triggered of high levels of antibodies: Rationale for the development of T cells focused vaccines April 22, 2022
- The Framingham Study: Across 6 Decades, Cardiovascular Disease Among Middle-Aged Adults – mean life expectancy increased and the RLR of ASCVD decreased. Effective primary prevention efforts and better screening increased. April 22, 2022
Archives
Categories
Meta
-
2012pharmaceutical
-
Amandeep Kaur
-
Aashir Awan, Phd
-
Abhisar Anand
-
Adina Hazan
-
Alan F. Kaul, PharmD., MS, MBA, FCCP
-
alexcrystal6
-
anamikasarkar
-
apreconasia
-
aviralvatsa
-
David Orchard-Webb, PhD
-
danutdaagmailcom
-
Demet Sag, Ph.D., CRA, GCP
-
Dror Nir
-
dsmolyar
-
Ethan Coomber
-
evelinacohn
-
Gail S Thornton
-
Irina Robu
-
jayzmit48
-
jdpmd
-
jshertok
-
kellyperlman
-
Ed Kislauskis
-
larryhbern
-
Madison Davis
-
marzankhan
-
megbaker58
-
ofermar2020
-
Dr. Pati
-
pkandala
-
Rosalind Codrington, PhD
-
ritusaxena
-
Rick Mandahl
-
sjwilliamspa
-
Srinivas Sriram
-
stuartlpbi
-
Dr. Sudipta Saha
-
tildabarliya
-
vaishnavee24
-
zraviv06
-
zs22
-
Leave a Reply